Notification of Major Interest in Shares

26/02/2009

NOTIFICATION OF MAJOR INTEREST IN SHARES
1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached (ii):

ReGen Therapeutics Plc

2. Reason for the notification:

An acquisition or disposal of voting rights

3. Full name of person(s) subject to the notification obligation (iii):

Barclays PLC

4. Full name of shareholder(s) (if difference from 3):

Barclays Stockbrokers Ltd
5. Date of the transaction and date on which the threshold is crossed or reached (v):

23rd February 2009

6. Date on which issued notified:

25th February 2009

7. Threshold(s) that is/are crossed or reached:

6% to 5%

8. Notified details

A: Voting rights attached to shares

Class/type of share if possible using the ISIN Code  GB00B28XMY25

Situation Previous to the triggering transaction (vi) –
Number of Shares    1,051,027
Number of Voting Rights (viii)  1,051,027

Resulting situation after the triggering transaction (viii) –
Number of Shares    1,051,027
Number of Voting Rights – Direct (x)  N/A
Number of Voting Rights – Indirect (xi)  1,051,027
% of voting rights – Direct   N/A
% of voting rights – Indirect   5.80

 

B: Financial Instruments

Resulting situation after the triggering transaction (xii)

Type of financial instrument    N/A

Expiration date (xiii)    N/A

Exercise/Conversion Period/Date (xiv)   N/A

Number of voting rights that may be acquired if the
instrument is exercised/converted   N/A

% of voting rights     N/A

Total (A+B)

Number of voting rights     1,051,027

% of voting rights     5.80
9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable (xv): Barclays Stockbrokers Ltd
Proxy Voting:

10. Name of the proxy holder:                                                N/A

11. Number of voting rights proxy holder will cease to hold:              N/A

12. Date on which proxy holder will cease to hold voting rights:        N/A

13. Additional information:                                N/A

14. Contact name:                                        Geoff Smith

15. Contact telephone number:     0207 116 2913

 

For further information:

For further information, please contact:

Percy Lomax
ReGen Therapeutics Plc
Tel: 020 7153 4920
Roland Cornish/Felicity Geidt
Beaumont Cornish Limited
Tel: 020 7628 3396